These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35315290)

  • 1. Nanotechnology-based therapeutics for targeting inflammatory lung diseases.
    Loo CY; Lee WH
    Nanomedicine (Lond); 2022 May; 17(12):865-879. PubMed ID: 35315290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases.
    Liao W; Dong J; Peh HY; Tan LH; Lim KS; Li L; Wong WF
    Molecules; 2017 Jan; 22(1):. PubMed ID: 28106744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential.
    Vij N
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1105-9. PubMed ID: 21711085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.
    Chung KF; Caramori G; Adcock IM
    Eur J Clin Pharmacol; 2009 Sep; 65(9):853-71. PubMed ID: 19557399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Drug Targeting using siRNA-based Nano Therapeutics for Pulmonary Diseases.
    Krishnaswami V; Kandasamy R
    Curr Pharm Des; 2022; 28(28):2279-2282. PubMed ID: 35894459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases.
    Pramanik S; Mohanto S; Manne R; Rajendran RR; Deepak A; Edapully SJ; Patil T; Katari O
    Mol Pharm; 2021 Oct; 18(10):3671-3718. PubMed ID: 34491754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives.
    Plichta J; Kuna P; Panek M
    Front Immunol; 2023; 14():1207641. PubMed ID: 37334374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
    Hanania NA
    Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases.
    Gulati N; Chellappan DK; MacLoughlin R; Gupta G; Singh SK; Oliver BG; Dua K; Dureja H
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):3695-3707. PubMed ID: 38078921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases.
    Passi M; Shahid S; Chockalingam S; Sundar IK; Packirisamy G
    Int J Nanomedicine; 2020; 15():3803-3826. PubMed ID: 32547029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.
    Zhang M; Lu H; Xie L; Liu X; Cun D; Yang M
    Adv Drug Deliv Rev; 2023 Dec; 203():115144. PubMed ID: 37995899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.
    Mehta M; Deeksha ; Tewari D; Gupta G; Awasthi R; Singh H; Pandey P; Chellappan DK; Wadhwa R; Collet T; Hansbro PM; Kumar SR; Thangavelu L; Negi P; Dua K; Satija S
    Chem Biol Interact; 2019 Aug; 308():206-215. PubMed ID: 31136735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biocomposite-based nanostructured delivery systems for the treatment and control of inflammatory lung diseases.
    Mukherjee D; Bhatt S
    Nanomedicine (Lond); 2022 May; 17(12):845-863. PubMed ID: 35477308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pulmonary medicine: asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis].
    Castro AFTE; Chucri S; Adler D; Janssens JP
    Rev Med Suisse; 2020 Jan; 16(676-7):81-86. PubMed ID: 31961091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
    Sin DD; Man SF
    Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary delivery of anti-inflammatory agents.
    Ali ME; McConville JT; Lamprecht A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):929-45. PubMed ID: 25534260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.
    Iyer R; Hsia CC; Nguyen KT
    Curr Pharm Des; 2015; 21(36):5233-44. PubMed ID: 26412358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD009039. PubMed ID: 21901729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting defective pulmonary innate immunity - A new therapeutic option?
    Belchamber KBR; Donnelly LE
    Pharmacol Ther; 2020 May; 209():107500. PubMed ID: 32061706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.